Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Verrica Pharmaceuticals (VRCA) PT Lowered to $13 at RBC Capital
August 15, 2024 6:16 AM EDTRBC Capital analyst Daniel Busby lowered the price target on Verrica Pharmaceuticals (NASDAQ: VRCA) to $13.00 (from $14.00) while maintaining a Outperform rating.
The analyst comments "VRCA's 2Q report shows steady progress for YCANTH through its molluscum contagiosum launch as distribution network expands; although aspects such as... More
Verrica Pharmaceuticals Inc. (VRCA) Tops Q2 EPS by 4c
August 14, 2024 7:46 AM EDTVerrica Pharmaceuticals Inc. (NASDAQ: VRCA) reported Q2 EPS of ($0.37), $0.04 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $5.18 million versus the consensus estimate of $4.58 million.
For earnings history and earnings-related data on Verrica Pharmaceuticals Inc. (VRCA) click here.
... More